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Synthesis, gallium-68 radiolabelling and biological
evaluation of a series of triarylphosphonium-
functionalized DO3A chelators†
Adam J. Smith, a,b Peter J. Gawne, a,b Michelle T. Ma, b Philip J. Blower, b
Richard Southworth *b and Nicholas J. Long *a
Radiolabelled lipophilic cations that accumulate in mitochondria according to the magnitude of the mito-
chondrial membrane potential can be used to report non-invasively on mitochondrial dysfunction in
cardiovascular disease, cardiotoxicity, and cancer. While several such cations are already commercially
available for SPECT imaging, PET offers greater promise in terms of sensitivity, resolution, and capacity for
dynamic imaging and pharmacokinetic modelling. We have therefore synthesised a series of three triaryl-
phosphonium-functionalised DO3A chelators for positron emitter gallium-68, with differing alkyl-func-
tionalisation motifs to provide opportunities for tunable lipophilicity as a means of optimising their phar-
macokinetics. To assess their capacity to report on mitochondrial membrane potential, we assessed their
pharmacokinetic profiles in isolated tumour cells and isolated perfused rat hearts before and after
mitochondrial depolarisation with the ionophore CCCP. All three compounds radiolabelled with over
97% RCY and exhibited logD values of between −3.12 and −1.81. In vitro assessment of the uptake of the
radiotracers in cultured tumour cells showed a three-fold increase in uptake compared to unchelated
[68Ga]Ga(III). However, each complex exhibited less than 1% retention in healthy hearts, which was not
significantly diminished by mitochondrial depolarisation with CCCP. This preliminary work suggests that
while this approach is promising, the lipophilicity of this class of tracers must be increased in order for
them to be useful as cardiac or cancer imaging agents.
Introduction
Lipophilic cations are widely used to map myocardial per-
fusion by means of SPECT, and to a lesser extent, PET
imaging. They can accumulate in the mitochondrial matrix in
a manner dependent on mitochondrial membrane potential
(ΔΨm), which in normally functioning mitochondria is
between 150–180 mV.1–4 In lipophilic cations that have been
successfully used as probes of ΔΨm, the charge is delocalised
over a large molecular surface area and as such, the tracers
can pass easily through the lipid bilayer membrane.2
Application of the Nernst equation to monocations predicts
100- to 500-fold accumulation compared to the extracellular
space, and at 37 °C, mitochondrial uptake of lipophilic cations
increases 10-fold for every 61.5 mV increase in ΔΨm.1,2 This
means that the degree of uptake of lipophilic cations can be
related to mitochondrial function or dysfunction; for example,
compared to healthy mitochondria, ΔΨm is reduced to below
100 mV in myocardial tissue recovering from reperfusion
injury, and at least 60 mV higher in tumour cells, and the
uptake of lipophilic cations varies accordingly.5,6
This basic concept has long been used experimentally to
report on ΔΨm through the use of fluorescent lipophilic
cations such as tetramethylrhodamine (TMRE), BODIPY and
Rhodamine-123.7–9 These tracers show great utility in cell
culture and isolated tissue preparations, however the poor
depth penetration and lack of whole body scanning inherent
to fluorescent tracers limits their overall utility. On the other
hand, nuclear medicine imaging methodologies such as
SPECT and PET provide unparalleled depth penetration, allow-
ing whole body imaging; clinically, SPECT-based lipophilic
cations such as [99mTc]Tc-sestaMIBI (Fig. 1) and [99mTc]Tc-
tetrofosmin (t1
2
= 6 h) are used.10–13 A clinical PET “equivalent”
to the SPECT radiopharmaceuticals [99mTc]Tc-sestaMIBI and
[99mTc]Tc-tetrofosmin would enable higher resolution
imaging, and potential detection of anatomically smaller
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tissue defects with aberrant ΔΨm. In addition, PET radiotracers
allow for dynamic imaging, so that the kinetics of influx and
efflux can be easily followed. It should also be noted that there
exist examples of multimodal optical/PET imaging agents,
which consist of a fluorophore functionalised with a PET
radioisotope.14–16 These compounds allow for the combination
of the high resolution of optical imaging with the depth pene-
tration of PET imaging.
PET radioisotopes such as carbon-11 and fluorine-18 (t1
2
=
20 and 109.7 min respectively) have previously been incorpor-
ated into lipophilic triphenylphosphonium (TPP) cations. TPP
is widely known to target mitochondria since the cationic
charge nominally residing on the phosphorus atom can be
delocalised around the aromatic rings.3,4,17,18 The first PET
tracer to utilise TPP was designed by Fukuda et al. and con-
sisted of TPP methylated with carbon-11 (methylTPP).19 Since
then, there have been many different types of TPP-functiona-
lised PET tracers for mitochondrial imaging, most commonly
using fluorine-18 since its longer half-life facilitates clinical
imaging.20–25 Recently, our group has synthesised the
MitoPhos series of tracers, which are fluorine-18 radiolabelled
alkyl-functionalised triarylphosphonium (TAP) cations, in order
to provide radiotracers with tunable lipophilicity. One example
of this series is [18F]MitoPhos_07, shown in Fig. 1.26,27
Metallic PET radioisotopes, such as copper-64 and gallium-
68 (t1
2
= 12.7 h and 68 min respectively) have the advantage that
once the chelator has been synthesised, the radiometal can be
added via a simple final synthetic step. Chelators such as
DO3A-xy-TPP, which consist of a DO3A chelating moiety,
a xylyl linking group (xy) and a TPP cation, have been shown
to chelate copper-64 to form effective tumour imaging
agents.28–30 Unlike cyclotron-produced copper-64, gallium-68
is generator-produced, and so has the potential to be more
widely used as generators become clinically widespread.31–34
There has been some preliminary work on synthesising
gallium-labelled lipophilic cations for mitochondrial imaging
e.g. Kardashinsky et al. have synthesised DO3A-xy-TAP chela-
tors for gallium-67, in which the TAP groups exhibit methyl
and pyridyl functionalisation.35–37 However, no mitochondrial
uptake studies have been performed on these chelators, and
their utility as gallium-68 based imaging agents has yet to be
explored.
In this study, we present a series of DO3A chelators for
gallium-68 complexation, functionalised with triphenylpho-
sphonium, tritolylphosphonium (TTP) and trixylylphospho-
nium (TXP) (Fig. 2). These chelators are designed to combine
the rationale behind the DO3A-xy-TPP chelators previously
used for copper-64 and gallium-67 chelation, with tunable
lipophilicity afforded by alkyl-functionalised triarylphospho-
nium cations in order to form the novel chelators DO3A-xy-
TTP and DO3A-xy-TXP.27,29,37 After initial synthesis and charac-
terisation of the ligands, their radiolabelling characteristics
and logD values were analysed to give an indication of their
potential use as mitochondrial imaging agents. The tracers
Fig. 1 [99mTc]Tc-sestaMIBI and [18F]MitoPhos_07, two examples of
lipophilic and cationic radiotracers.10,27
Fig. 2 The three gallium-68 chelate complexes synthesised in this
study: [68Ga]Ga-DO3A-xy-TPP, [68Ga]Ga-DO3A-xy-TTP and [68Ga]Ga-
DO3A-xy-TXP.
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were biologically evaluated in cultured tumour cells and using
the ex vivo Langendorff isolated perfused heart model with a
unique triple gamma detector system, which has been used
previously in our group to assess radiotracer
pharmacokinetics.38–41
Results
Synthesis of the DO3A-xy-TAP chelators
DO3A-xy-TAP chelators were synthesised as outlined in
Scheme 1. The synthesis combined methodologies used by
Haslop et al., Wang et al. and Kardashinsky et al.27,28,37 Firstly,
an alkyl-functionalised aryl bromide was converted into a
Grignard reagent before being reacted with phosphorus tri-
chloride to form a triarylphosphine (1). This strategy allowed
tuning of the final tracer lipophilicity by altering the alkyl
functionalisation, in accordance with the work performed by
Haslop et al.27 Whilst anaerobic and anhydrous conditions
were maintained as far as possible, some triarylphosphine was
found by 31P{1H}-NMR to be oxidised to its phosphine oxide.
The phosphine oxide impurity did not require additional puri-
fication, since it was inert during the subsequent nucleophilic
substitution step due to the lack of a phosphorus-centred lone
pair.
Secondly, the triarylphosphine was reacted with α,α′-
dibromo-m-xylene to form the phosphonium compound and
incorporate the xylyl linking group (2). Wang et al. performed
this reaction at 100 °C in toluene, forming a mixture of the
desired monosubstituted product as well as starting material
and disubstituted impurities.28 Instead, we performed the
reaction at the lowest temperature at which the dibromoxylene
fully dissolves in toluene, i.e. 60 °C. At this temperature, as 2
forms, it precipitates out of the non-polar toluene solvent, and
thus can be readily isolated by vacuum filtration.
The monocationic bromoxylene phosphonium derivative 2
was then reacted with tris-tert-butyl-protected DO3A hydrobro-
mide to form TAP-functionalised DO3A derivatives (3).42 Using
sodium carbonate as an inorganic base allowed for the purifi-
cation by recrystallisation of the tris-tert-butyl protected inter-
mediate, as well as its characterisation by NMR. The final step
was deprotection of the tert-butyl protected carboxylates (3)
using trifluoroacetic acid, followed by purification by semipre-
parative reverse-phase HPLC.
Radiolabelling studies of DO3A-xy-TAP with [68Ga]GaCl3 eluate
All three DO3A-xy-TAP compounds were radiolabelled and ana-
lysed using the same protocol. The ligand was dissolved in
aqueous ammonium acetate solution in order to partially neu-
tralise the acidic generator eluate containing [68Ga]Ga(III).
Next, the [68Ga]Ga(III) eluate was added, and the resulting
mixture was heated at 100 °C for 30 minutes. As a quality
control (QC) method, instant thin-layer chromatography (iTLC)
was employed, using a mobile phase of 0.1 M EDTA, in which
unchelated [68Ga]Ga(III) migrated to the solvent front, and left
the cationic complex, which resisted transchelation to EDTA,
on the baseline. iTLC analysis gave RCY values of 98, 100 and
97% for 100 μM concentrations of [68Ga]Ga-DO3A-xy-TPP, TTP
and TXP respectively. Due to the high RCY of the three radiola-
belling processes, no post-purification was undertaken.
Finally, the reaction mixture was analysed by radioHPLC to
determine whether a single complex had formed and to give
an initial indication of its lipophilicity. The radioHPLC traces
obtained for the three compounds are shown in normalised
form in Fig. 3. In each trace, a small peak can be seen at
approximately 2 minutes, which corresponds to unreacted/
non-chelated [68Ga]Ga(III) species, and a single major peak
corresponding to the complex, showing no evidence of isomer-
ism. The relative retention times of the three compounds
provide an insight into the lipophilicities of the three com-
pounds. As can be seen from Fig. 2, increased TAP alkylation
results in a longer retention time on a reverse-phase C-18
column, and indicates relatively greater lipophilicity. This
trend is also seen in analogous HPLC traces of the unchelated
Scheme 1 Synthesis of DO3A-xy-TAP chelators. DO3A tris-tBu·HBr was
synthesised according to previously reported procedures.42 Reaction
conditions: (i) Mg then PCl3, dry THF, anaerobic conditions; (ii) α,α’-
dibromo-p-xylene, toluene, 60 °C; (iii) DO3A tris-tBu·HBr, Na2CO3,
MeCN, reflux; (iv) TFA, semi-prep HPLC. The choice of the aryl bromide
determines which DO3A-xy-TAP variant is synthesised: Ar = phenyl,
DO3A-xy-TPP; Ar = tolyl, DO3A-xy-TTP; Ar = m-xylyl, DO3A-xy-TXP.
Fig. 3 RadioHPLC traces of the three labelled [68Ga]Ga-DO3A-xy-TAP
compounds (eluent gradient: 100% A for 5 min; 0–80% B in A for 20 min;
100% A for 5 min; flow rate 1 mL min−1). All traces have been normalised
such that the maximum activity measured for each compound is equal
to 1.
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ligands; the retention times of which are summarised in
Table 1. The unchelated ligands also show shorter HPLC reten-
tion times by HPLC than their gallium-68-labelled counter-
parts, which indicates an increase in lipophilicity upon chela-
tion, a result of the hydrophilicity of the carboxylate arms
decreasing upon binding to the metal centre.
Lipophilicity measurements of [68Ga]Ga-DO3A-xy-TAP
compounds
To measure the lipophilicities of the radiotracers, their
octanol/PBS partition coefficients at pH 7.4 (logD) were deter-
mined using a conventional ‘shake-flask’ method. The logD
values, shown in Fig. 4, were determined to be −3.12 ± 0.17,
−2.66 ± 0.09 and −1.81 ± 0.02 for [68Ga]Ga-DO3A-xy-TPP, TTP
and TXP respectively (n = 6 for all compounds).
In vitro quantification of [68Ga]Ga-DO3A-xy-TXP uptake in
tumour cells
Intracellular/extracellular concentration ratios for [68Ga]Ga-
DO3A-xy-TXP and unchelated [68Ga]Ga(III) in breast cancer cells
(MDA-MB 231) in vitro were calculated, and are summarised in
Fig. 5. [68Ga]Ga-DO3A-xy-TXP shows a ratio of 10.03 ± 0.45,
indicating that the tracers localise inside the tumour cells. In
comparison, [68Ga]Ga(III) shows a ratio of 3.43 ± 0.39, indicat-
ing that the chelator facilitates a three-fold increase in radio-
tracer uptake compared to unchelated [68Ga]Ga(III). A trypan
blue cell viability study showed over 90% of cells used in both
the [68Ga]Ga-DO3A-xy-TXP and control experiments survived.
Quantification of [68Ga]Ga-DO3A-xy-TXP myocardial uptake
using the Langendorff isolated perfused heart model
We have previously made use of the Langendorff isolated per-
fused heart model to provide an ex vivo assessment of myocar-
dial radiotracer uptake, with a unique triple radiodetector
system which allows for accurate determination of time-activity
curves.38–41 The time-activity curves for each of the three radio-
detectors quantify radiotracer entering the heart (arterial
detector), radiotracer retention in the heart (heart detector)
and radiotracer exiting the heart (venous detector). The ex vivo
nature of the experiment means that the behaviour of the
tracer in the myocardium can be evaluated accurately and
reproducibly without the complications of the in vivo setting
such as aberrant metabolism or regional changes in perfusion,
and haemodynamic parameters can be easily monitored,
whilst maintaining constant perfusion to determine the
specific contribution of mitochondrial membrane potential to
tracer pharmacokinetics.
To assess radiotracer uptake under conditions in which
ΔΨm is reduced, the heart was infused with a 600 nM solution
of the ionophore carbonyl cyanide m-chlorophenyl hydrazone
(CCCP).43 We have previously found that this concentration is
optimal to effect complete ΔΨm depolarisation, validated
using the clinical SPECT radiopharmaceutical, [99mTc]Tc-
sestaMIBI (Fig. 1) to ensure validity of the model for this set
of experiments.44 As shown in Fig. 6A and summarised in
Fig. 6B, [99mTc]Tc-sestaMIBI demonstrates 30 ± 0.03% (n = 4)
radiotracer retention after 15 minutes in hearts under normal
conditions, but 0 ± 0.04% (n = 4) retention after 15 minutes in
hearts under depolarising conditions.12
[68Ga]Ga-DO3A-xy-TXP (1 MBq) was injected as a bolus into
the flow of Krebs buffer. Arterial influx, myocardial retention
and venous efflux of radiotracer were measured using each
Table 1 Retention times (in minutes) of the unchelated DO3A-xy-TAP
ligands, along with their gallium-68-radiolabelled analogues as
measured by HPLC. HPLC conditions are identical to those described in
Fig. 3
Ar= Unchelated ligand [68Ga]Ga complex
TPP 14.3 14.8
TTP 17.2 17.6
TXP 18.5 19.9
Fig. 4 LogD values obtained of the three labelled [68Ga]Ga-DO3A-xy-
TAP compounds. Data are mean ± SD (n = 6).
Fig. 5 Results of the in vitro tumour cell uptake experiment for [68Ga]
Ga-DO3A-xy-TXP and unchelated [68Ga]Ga(III) control. Measurements
were taken in triplicate. Data are mean ± SD. * = P < 0.05.
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respective γ-detector (Fig. 6A and C) for 15 min. Then, to
assess radiotracer uptake under depolarising conditions, the
same heart was infused with CCCP. After 5 min of infusion
with CCCP, the second bolus of [68Ga]Ga-DO3A-xy-TXP was
injected, and the passage of radioactivity through the per-
fusion system was monitored using the three γ-detectors. As
shown by Fig. 6C, most of the injected [68Ga]Ga-DO3A-xy-TXP
washed out of the heart within 3 minutes of bolus adminis-
tration, irrespective of whether the mitochondria were
depolarised. This stands in contrast to the control data for
mitochondrial depolarisation dependant uptake of [99mTc]Tc-
sestaMIBI discussed previously. The average retained gallium-
68 activity between 14–15 minutes post-injection over 3 experi-
ments is reported in Fig. 6D. [68Ga]Ga-DO3A-xy-TXP showed
1% retention in both control and CCCP-infused hearts. Over 3
experiments, there was no statistically significant difference
between [68Ga]Ga-DO3A-xy-TXP retention in control and CCCP
infused hearts.
Discussion
The series of DO3A-xy-TAP compounds was designed to be
simple to synthesise and purify, whilst also being easy to
modify in order to generate a series of compounds with
tunable lipophilicity. Unlike other syntheses of TAP-functiona-
lised DO3A compounds, this work utilises a highly modular
approach, which allows a library of compounds to be syn-
thesised using identical reaction protocols. Use of a lower reac-
tion temperature during formation of the phosphonium cation
allows for the facile isolation of the pure target compound,
which is especially useful given the difficulties in purifying
phosphonium cations using column chromatography.
Upon radiolabelling, the three gallium-68 radiolabelled
compounds synthesised all show high RCY values above 97%,
despite the size mismatch between DO3A and Ga(III) cations.
Whilst DO3A is not an ideal chelator for Ga(III) cations since
radiolabelling requires heating and lengthy reaction times, it
was chosen for the simplicity of its functionalisation chem-
istry. A useful part of this work is the method for the QC of
gallium-68 labelled lipophilic cations. Basing this method on
the facile chelation of Ga(III) by EDTA means that this method
should be easily applicable to future syntheses of all gallium-
68 labelled lipophilic cations.
Functionalisation of the TAP moiety with alkyl groups has
been shown to dramatically affect the lipophilicity of the radio-
tracers with a 0.5 unit difference between the TPP and TTP-
functionalised compounds, and a 0.8 unit difference between
the TTP and TXP-functionalised compounds. It is interesting
that even when conjugated to the bulky and hydrophilic DO3A
chelator, such a small change as the addition of three methyl
groups to the TPP group has such a dramatic effect on the
log D values. The log D values of the compounds are low when
compared to other lipophilic cationic compounds such as
Fig. 6 (A and C) Representative example of data output of the triple-gamma detector system for [99mTc]Tc-sestaMIBI and [68Ga]Ga-DO3A-xy-TXP
respectively. (B and D) Retention values obtained using the two-injection protocol 15 minutes post-injection for [99mTc]Tc-sestaMIBI and [68Ga]Ga-
DO3A-xy-TXP respectively. Control data were obtained from the injection before CCCP infusion, whilst CCCP data were obtained during 600 nM
CCCP infusion. Data for [99mTc]Tc-sestaMIBI are mean ± SD (n = 4). * = P < 0.05. Data for [68Ga]Ga-DO3A-xy-TXP are mean ± SD (n = 3).
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[99mTc]Tc-sestaMIBI, which has a log D value of 1.29.45
Nevertheless, it was decided to assess the tracer ex vivo as
there is precedent of cations with low log D values crossing
lipid bilayer membranes.25,46
Uptake experiments with [68Ga]Ga-DO3A-xy-TXP in tumour
cells were undertaken in vitro, due to the high ΔΨm values
often found in tumour cells.1,2,6,47–49 In this study, [68Ga]Ga-
DO3A-xy-TXP showed a three-fold increase in uptake in the
cancer cell line when compared to unchelated [68Ga]Ga(III),
indicating that the chelator facilitates uptake of gallium-68
into tumour cells.
Analysis using the perfused heart model showed no statisti-
cally significant difference in [68Ga]Ga-DO3A-xy-TXP retention
between healthy and CCCP-infused hearts. In addition, the
cardiac uptake of our compounds was low when compared to
the parallel study performed using [99mTc]Tc-sestaMIBI. This
is likely a result of the lower lipophilicity of [68Ga]Ga-DO3A-xy-
TXP hindering passage through the lipid bilayer membrane.
Since the membrane potential in a normally functioning heart
does not facilitate uptake of these tracers in cardiac cells, there
will then be no difference in uptake once the mitochondria
have been depolarized by CCCP infusion. This preliminary
work suggests that while this approach is promising from a
synthetic strategy perspective, the lipophilicity of this class of
tracers must be increased in order for them to be useful as
cardiac or cancer imaging agents.
Conclusions
We have synthesised a series of TAP-functionalised DO3A
ligands for gallium-68 chelation with a view to synthesising
lipophilic cationic radiotracers. The synthetic methodology
developed is effective and entirely modular, and can be the
basis of a strategy for synthesising libraries of tracers with
tunable lipophilicities, by varying the chelator, linker and cation.
The results encourage the development of future gallium-68
labelled lipophilic cations with chelators more appropriate for
the efficient formation of lipophilic and positively charged
complexes of gallium-68.
Experimental procedures
Materials and instrumentation
Commercially available reagent grade solvents and chemicals
were used without further purification. All gas mixtures were
purchased from BOC Industrial Gases. 1H, 13C{1H}, 19F{1H},
31P{1H}, COSY, HSQC, and HMBC NMR spectra were obtained
using a Bruker AVIII 400 spectrometer. High Resolution
Electrospray Mass Spectrometry was carried out on a Waters
LCT Premier (ES-ToF)/Acquity i-Class spectrometer. HPLC was
performed on an Agilent 1200 Series Liquid Chromatograph
with UV and LabLogic Flow-Count detector with a sodium-
iodide probe (B-FC-3200). Mobile phase A contained water
with 0.1% TFA, and mobile phase B contained MeCN with
0.1% TFA. Semi-preparative reverse phase HPLC was con-
ducted using an Agilent Eclipse XDB-C18 column (21.2 ×
150 mm, 5 μm) with a 5 mL min−1 flow rate and UV spectro-
scopic detection at 214 nm. Analytical reverse phase HPLC was
conducted using an Agilent Eclipse XDB-C18 column (4.6 ×
150 mm, 5 μm) with a 1 mL min−1 flow rate and UV spectro-
scopic detection at 250 nm. Gallium-68 was eluted as
[68Ga]GaCl3 from an Eckert and Ziegler gallium-68 generator
using a 0.1 M solution of hydrochloric acid.
Synthesis
Synthesis of tris(3,5-dimethylphenyl)phosphane (1c) was
performed according to previously reported literature pro-
cedures by Haslop et al.27 Synthesis of 1,4,7-tris(tert-butoxy-
carbonylmethyl)-1,4,7,10-tetraazacyclododecane hydrobromide
(DO3Atriester·HBr) was performed according to previously
reported literature procedures by Jagadish et al.42
Tri-p-tolylphosphane (1b). This compound was originally
synthesised by Mann et al.50 The methodology used here was a
modification of the procedure described by Haslop et al.27
A solution of 4-bromotoluene (2.89 mL, 23.5 mmol) in an-
hydrous THF (10 mL) was added dropwise whilst maintaining
reflux to magnesium turnings (0.57 g, 23.5 mmol) in a Schlenk
flask under N2. The resulting suspension was stirred for 2 h
before a solution of PCl3 (0.69 mL, 7.8 mmol) in anhydrous
THF (15 mL) was added dropwise whilst maintaining reflux,
and the resulting mixture was stirred for a further 2 h. The
reaction was quenched with water (10 mL), and the organic
phase was isolated. The organic solvent was removed under
reduced pressure to yield the title compound as a pale yellow
solid (0.96 g, 40%). 1H-NMR (400 MHz, CDCl3) δH (ppm): 7.24
(6H, m), 7.17 (6H, m), 2.38 (9H, s, CH̲3).
13C{1H}-NMR
(100 MHz, CDCl3) δc (ppm): 138.6, 133.8, 129.4, 129.3, 21.4.
31P{1H}-NMR (162 MHz, CDCl3) δP (ppm): −7.9. HRMS
(ES-TOF+): m/z calcd for C21H22P ([M + H]
+) 305.1459, found
305.1445.
General procedure 1: monosubstitution of α,α′-dibromo-p-
xylene with aryl-functionalized triarylphosphines (2)
The methodology used was a modification of the procedure
described by Wang et al.28 α,α′-Dibromo-p-xylene (1 eq.) was
added to toluene (5 mL) and heated to 60 °C until all the solid
had dissolved. To this, a solution of the triarylphosphine
(1 eq.) in toluene (6 mL) was added dropwise, before the result-
ing solution was stirred at 60 °C under an N2 atmosphere over-
night. The white precipitate was isolated by filtration, before
being washed with toluene (5 mL) and Et2O (2 × 10 mL), then
dried in vacuo to yield the desired product.
(4-(Bromomethyl)benzyl)triphenylphosphonium bromide (2a).
This compound was originally synthesised by Wang et al.28
Following general procedure 1, the title compound was pre-
pared from α,α′-dibromo-p-xylene (0.53 g, 2 mmol) and tri-
phenylphosphine (0.54 g, 2 mmol) as a white solid (0.86 g,
82%). 1H NMR (400 MHz, CDCl3) δH (ppm): 7.73 (9H, m,
m/p-Ar), 7.60 (6H, m, o-Ar), 7.11 (4H, d, 3JHH = 1.3 Hz, C6H ̲4),
5.50 (2H, d, 2JHP = 14.6 Hz, CH̲2P), 4.37 (2H, d,
4JHH = 1.3 Hz,
Paper Dalton Transactions
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CH̲2Br).
13C{1H}-NMR (100 MHz, CDCl3) δC (ppm): 138.2 (d,
4JCP = 4.4 Hz, p-Ar), 135.1 (d,
5JCP = 2.8 Hz), 134.5 (d,
2JCP =
9.3 Hz, o-Ar), 132.1 (d, 3JCP = 6.1 Hz, C̲6H4), 130.3 (d,
3JCP =
6.1 Hz, m-Ar), 129.5 (d, 4JCP = 3.5 Hz, C̲6H4), 127.9 (d,
3JCP =
8.8 Hz), 117.9 (d, 1JCP = 85.9 Hz, i-Ar), 33.0 (C̲H2Br), 30.5
(d, 1JCP = 47.2 Hz, C ̲H2P). 31P{1H}-NMR (162 MHz, CDCl3)
δP (ppm): 23.5. HRMS (ES-TOF+): m/z calcd for C26H23BrP
([M − Br]+) 445.0721, found 445.0737.
(4-(Bromomethyl)benzyl)tri-p-tolylphosphonium bromide (2b).
Following general procedure 1, the title compound was
prepared from α,α′-dibromo-p-xylene (0.53 g, 2 mmol) and tri-
p-tolylphosphane (0.72 g, 2 mmol) as a white solid (1.04 g,
92%). 1H NMR (400 MHz, CDCl3) δH (ppm): 7.54 (6H, m,
m-Ar), 7.38 (6H, dd, 3JHP = 8.2,
3JHH = 3.2 Hz, o-Ar), 7.13 (2H, d,
3JHH = 8.1 Hz, C6H ̲4), 7.08 (2H, dd, 3JHH = 8.4, 4JHP = 2.4 Hz,
C6H ̲4), 5.24 (2H, d, 2JHP = 14.5 Hz, CH̲2P), 4.38 (2H, s, CH2̲Br),
2.44 (9H, s, CH̲3).
13C{1H}-NMR (100 MHz, CDCl3) δC (ppm):
146.3 (d, 5JCP = 2.6, Hz, C̲6H4), 138.1 (d,
4JCP = 3.9 Hz, o-Ar),
134.3 (d, 2JCP = 10.4 Hz, p-Ar), 132.0 (d,
3JCP = 5.7 Hz, C̲6H4),
130.4 (d, 3JCP = 3.4 Hz, m-Ar), 129.5 (d,
4JCP = 3.6 Hz, C̲6H4),
128.1 (d, 2JCP = 8.6 Hz, C̲6H4), 114.6 (d,
1JCP = 88.7 Hz, i-Ar),
33.1 (C ̲H2Br), 30.9 (d, 1JCP = 48.1 Hz, C̲H2P), 22.0 (C ̲H3).
31P{1H}-NMR (162 MHz, CDCl3) δP (ppm): 22.4. HRMS
(ES-TOF+): m/z calcd for C29H29BrP ([M − Br]+) 529.1660, found
529.1669. Anal. calcd for C29H29PBr2 (found): C, 61.29 (61.22);
H 5.14 (5.26).
(4-(Bromomethyl)benzyl)tris(3,5-dimethylphenyl)phosphonium
bromide (2c). Following general procedure 1, the title com-
pound was prepared from α,α′-dibromo-p-xylene (0.53 g,
2 mmol) and tris(3,5-dimethylphenyl)phosphane (0.87 g,
2 mmol) as a white solid (2.74 g, 88%). 1H NMR (400 MHz,
CDCl3) δH (ppm): 7.34 (3H, s, p-Ar), 7.21 (6H, d,
3JHP = 13.0 Hz,
o-Ar), 7.15 (2H, d, 3JHH = 7.6 Hz, C6H4̲), 7.02 (2H, dd,
3JHH =
8.0, 4JHP = 2.7 Hz, C6H̲4), 5.21 (2H, d,
2JHP = 14.3 Hz, CH̲2P),
4.40 (2H, s, CH̲2Br), 2.36 (18H, s, CH̲3).
13C{1H}-NMR
(100 MHz, CDCl3) δC (ppm): 140.3 (d,
2JCP = 12.3 Hz, C̲6H4),
138.0 (d, 5JCP = 3.5 Hz, C̲6H4), 136.8 (d,
4JCP = 3.5 Hz, C̲6H4),
132.1 (d, 3JCP = 5.1 Hz, C̲6H4), 131.7 (d,
2JCP = 10.1 Hz, o-Ar),
129.3 (d, 4JCP = 3.5 Hz, p-Ar), 128.5 (d,
3JCP = 8.7 Hz, m-Ar),
117.8 (d, 1JCP = 84.5 Hz, i-Ar), 33.1 (C ̲H2Br), 30.9 (d, 1JCP =
46.6 Hz, C̲H2P), 21.5 (CH3̲).
31P{1H}-NMR (162 MHz, CDCl3)
δP (ppm): 22.7. HRMS (ES-TOF+): m/z calcd for C32H35BrP
([M − Br]+) 529.1660, found 529.1643. Anal. calcd for
C32H35PBr2 (found): C, 62.97 (62.98); H, 5.78 (5.73).
General procedure 2 – coupling of triarylphosphane-
substituted bromoxylene to DO3Atriester hydrobromide (3)
The methodology was a modification of the procedure
described by Kardashinsky et al.37 To a solution of
DO3Atriester·HBr (1 eq.) and triarylphosphane-substituted bro-
moxylene (1 eq.) in MeCN (15 mL), Na2CO3 (5 eq.) was added,
and the resulting suspension was heated to reflux and stirred
under an N2 atmosphere overnight. The inorganic base was
removed by filtration and the solvent removed under reduced
pressure. The resulting residue was recrystallized from
acetone/Et2O to yield the desired product.
Triphenyl(4-((4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl)methyl)benzyl)phosphonium bromide
(3a). Following general procedure 2, the title compound was
prepared from DO3Atriester·HBr (0.30 g, 0.5 mmol), 2a (0.26 g,
0.5 mmol) and Na2CO3 (0.26 g, 2.5 mmol) as a white solid
(0.37 g, 76%). 1H NMR (400 MHz, CDCl3) δH (ppm): 7.78 (3H,
tt, 3JHH = 6.9,
4JHH = 1.7 Hz, p-Ar), 7.74–7.63 (12H, m, o/m-Ar),
7.05–7.04 (4H, m, C6H ̲4), 5.33 (2H, broad s, CH̲2P), 3.64 (2H, s,
C6H4CH̲2), 3.41–2.11 (22H, m, macrocycle H̲/CH̲3CO2), 1.47
(18H, s, cis-C(CH̲3)3), 1.43 (9H, s, trans-C(CH3̲)3).
13C{1H}-NMR
(100 MHz, CDCl3) δC (ppm): 173.7 (C̲vO), 172.7 (C ̲vO), 135.6
(d, 5JCP = 4.0 Hz), 135.3 (d,
4JCP = 2.7 Hz), 134.4 (d,
3JCP =
9.8 Hz), 131.6 (d, 3JCP = 5.3 Hz), 130.9 (d,
4JCP = 1.8 Hz), 130.4
(d, 2JCP = 12.8 Hz), 129.9 (d,
2JCP = 8.7 Hz), 117.1 (d,
1JCP =
86.0 Hz), 83.1 (cis-C̲(CH3)3), 82.6 (trans-C̲(CH3)3), 57.9, 57.0, 50.9,
30.8 (d, 1JCP = 46.5 Hz, C̲H2P), 28.2 (C(C ̲H3)3), 28.0 (C(C ̲H3)3).
31P{1H}-NMR (162 MHz, CDCl3) δP (ppm): 23.1. HRMS
(ES-TOF+): m/z calcd for C52H72N4O6P ([M − Br]+) 879.5190,
C52H73N4O6P ([M − Br + H]2+) 440.2628, C52H74N4O6P ([M − Br
+ 2H]3+) 293.8443. Found: 879.5258, 440.2600, 293.8420.
Tri-p-tolyl(4-((4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl)methyl)benzyl)phosphonium bromide
(3b). Following general procedure 2, the title compound was
prepared from DO3Atriester·HBr (0.30 g, 0.5 mmol), 2b (0.28 g,
0.5 mmol) and Na2CO3 (0.26 g, 2.5 mmol) as a white solid
(0.23 g, 47%). 1H NMR (400 MHz, CDCl3) δH (ppm): 7.57–7.52
(6H, m, o-Ar), 7.43 (6H, dd, 3JHH = 8.3,
4JHH = 3.3 Hz, m-Ar),
7.07 (2H, dd, 3JHH = 8.3,
4JHH = 2.3 Hz, C6H ̲4), 7.03 (2H, d,
3JHH = 8.1 Hz, C6H ̲4), 5.18 (2H, d, 2JHP = 14.4 Hz, CH̲2P), 3.68
(2H, s, C6H4CH̲2), 3.43–2.18 (16H, m, macrocycle H̲) 3.04–3.00
(6H, m, CH̲2CO2), 2.47 (9H, s, ArCH̲3) 1.48 (18H, s, cis-C
(CH ̲3)3), 1.43 (9H, s, trans-C(CH̲3)3). 13C{1H}-NMR (100 MHz,
CDCl3) δC (ppm): 173.7 (C ̲vO), 172.7 (C ̲vO), 146.4 (C̲6H4),
135.6 (C̲6H4), 134.3 (d,
2JCP = 10.3 Hz, o-Ar), 131.5 (d,
4JCP = 6.4 Hz,
C̲6H4), 131.0 (d,
3JCP = 12.5 Hz, C̲6H4), 130.8 (m-Ar), 127.2 (d,
4JCP = 8.5 Hz, p-Ar), 114.6 (d,
1JCP = 88.7 Hz, i-Ar), 83.0
(C ̲(CH3)3), 82.6 (C̲(CH3)3), 58.0 (C6H4C̲H2), 56.9 (C ̲H2CO2), 56.0
(C̲H2CO2), 51.0 (broad, macrocycle C̲), 49.4 (broad, macrocycle C̲),
31.1 (d, 1JCP, CH̲2P), 28.2 (cis-C(C ̲H3)3), 28.0 (trans-C(C ̲H3)3),
22.0 (Ar-C ̲H3). 31P{1H}-NMR (162 MHz, CDCl3) δP (ppm): 22.1.
HRMS (ES-TOF+): m/z calcd for C55H78N4O6P ([M − Br]+)
921.5659, C55H79N4O6P ([M − Br + H]2+) 461.2863. Found:
921.5684, 461.2828.
Tris(3,5-dimethylphenyl)(4-((4,7,10-tris(2-(tert-butoxy)-2-
oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)methyl)benzyl)phos-
phonium bromide (3c). Following general procedure 2, the title
compound was prepared from DO3Atriester·HBr (0.30 g,
0.5 mmol), 2c (0.31 g, 0.5 mmol) and Na2CO3 (0.26 g,
2.5 mmol) as a white solid (0.36 g, 70%). 1H NMR (400 MHz,
CDCl3) δH (ppm): 7.35 (3H, s, p-Ar), 7.21 (6H, d,
3JHP = 13.1 Hz,
o-Ar), 7.11 (2H, d, 3JHH = 8.0 Hz), 7.05 (2H, dd,
3JHH = 8.2,
4JHP = 2.4 Hz), 5.15 (2H, d,
2JHP = 14.2 Hz, CH̲2P), 3.68 (2H, s),
3.05 (2H, s), 3.01 (4H, s), 2.97–2.16 (16H, m, macrocycle H̲),
2.36 (18H, s, Ar–CH̲3), 1.48 (18H, s, cis-C(CH̲3)3), 1.44 (9H, s,
trans-C(CH̲3)3).
13C{1H}-NMR (100 MHz, CDCl3) δC (ppm):
173.6 (C ̲vO), 172.7 (C ̲vO), 140.2 (d, 2JCP = 12.6 Hz, C̲6H4),
Dalton Transactions Paper
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136.8 (p-Ar), 135.9 (C̲6H4), 131.6 (o-Ar), 131.5 (C ̲6H4), 130.7
(C ̲6H4), 127.5 (d, 3JCP = 8.3 Hz, m-Ar), 117.7 (d, 1JCP = 84.9 Hz,
i-Ar), 82.9 (C ̲H2CO2), 82.5 (C̲H2CO2), 57.9 (C6H4C̲H2), 56.7
(C ̲H2CO2), 55.9 (C ̲H2CO2), 50.8 (broad, macrocycle C̲), 49.2
(broad, macrocycle C̲), 30.9 (d, 1JCP = 48.5 Hz, C̲H2P), 28.1 (cis-
C(C ̲H3)3), 27.9 (trans-C(C ̲H3)3), 21.5 (Ar-C̲H3). 31P{1H}-NMR
(162 MHz, CDCl3) δP (ppm): 22.4. HRMS (ES-TOF+): m/z calcd
for C58H84N4O6P ([M − Br]+) 963.6129, C58H85N4O6P ([M − Br +
H]2+) 482.3098. Found: 963.6139, 482.2990.
General procedure 3 – deprotection of tert-butyl protected
DO3A-xy-TAP compounds using trifluoroacetic acid (4)
The methodology was a modification of the procedure
described by Kardashinsky et al.37 tert-butyl protected com-
pounds were dissolved in trifluoroacetic acid (reaction mixture
concentration 0.1 g mL−1) and stirred at rt under an N2 atmo-
sphere for 24 h. The acid was removed in vacuo, before the
residue was taken up in H2O (50 mL) and washed with CHCl3
(3 × 10 mL). The aqueous solvent was removed under reduced
pressure, before the residue was purified via semi-preparative
HPLC methods.
DO3A-xy-TPP trifluoroacetate. Following general procedure
3, the title compound was prepared from 3a (0.25 g,
0.26 mmol) and trifluoroacetic acid (2.5 mL) as a white solid
(0.16 g, 73%). 1H NMR (400 MHz, MeOD) δH (ppm): 7.91 (3H,
td, 3JHH = 7.3,
4JHH = 1.8 Hz, p-Ar), 7.78–7.62 (12H, m, o,m-Ar),
7.51 (2H, d, 3JHH = 7.8 Hz, C6H̲4), 7.08 (2H, dd,
3JHH = 8.0,
4JHP = 2.7 Hz, C6H ̲4), 4.95 (2H, d, 2JHP = 15.1 Hz, CH̲2P), 4.34
(2H, s), 3.97 (2H, s), 3.64 (2H, s), 3.39 (4H, s), 3.29–3.02
(16H, m). 13C{1H}-NMR (100 MHz, MeOD) δC (ppm): 162.8
(C ̲vO), 162.5 (C ̲vO), 136.6 (p-Ar), 135.3 (3JCP = 9.1 Hz, m-Ar),
133.2 (3JCP = 5.2 Hz, C̲6H4), 131.5 (
2JCP = 13.6 Hz, o-Ar), 119.6
(C6̲H4), 119.0 (
1JCP = 86.9 Hz, i-Ar), 116.7 (C̲6H4), 58.5,
55.6, 54.1, 50.5 (broad s), 50.4 (broad s), 30.3 (1JCP = 48.6 Hz,
C̲H2P).
19F{1H}-NMR (377 MHz, MeOD) δF (ppm): −73.0.
31P{1H}-NMR (162 MHz, MeOD) δP (ppm): 26.8. HRMS
(ES-TOF+): m/z calcd for C40H48N4O6P ([M − CF3CO2]+)
711.3311, C40H49N4O6P ([M − CF3CO2 + H]2+) 356.1689. Found:
711.3320, 356.1727.
DO3A-xy-TTP trifluoroacetate. Following general procedure 3,
the title compound was prepared from 3b (0.21 g, 0.23 mmol)
and trifluoroacetic acid (2.1 mL) as a white solid (0.10 g, 57%).
1H-NMR (400 MHz, MeOD) δH (ppm): 7.58–7.52 (12H, m,
o/m-Ar), 7.47 (2H, d, 3JHH = 8.2 Hz, C6H̲4), 7.09 (2H, broad s,
C6H ̲4), 4.83 (2H, d, 2JHP = 15.3 Hz, CH̲2P), 4.48 (2H, broad s),
4.15 (2H, broad s), 3.78–3.43 (4H, m, CH̲2CO2H), 3.29–2.90
(16H, m, macrocycle H̲). 2.50 (9H, s, CH̲3).
13C{1H}-NMR
(100 MHz, MeOD) δC (ppm): 174.2 (C ̲vO), 171.7 (C ̲vO), 148.2
(p-Ar), 135.2 (d, 3JCP = 10.3 Hz, C̲6H4), 133.2 (d,
4JCP = 5.4 Hz,
C̲6H4), 132.0 (d,
2JCP = 12.4 Hz, o-Ar), 121.9 (C̲6H4), 119.0
(m-Ar), 115.7 (d, 1JCP = 90.2 Hz, i-Ar), 113.2 (C̲6H4), 58.6, 55.4,
53.6 (C̲H2CO2H), 50.8 (broad, macrocycle C̲), 30.7 (d,
1JCP =
48.7 Hz, C̲H2P), 21.8 (C ̲H3). 19F{1H}-NMR (377 MHz, MeOD)
δF (ppm): −77.3. 31P{1H}-NMR (162 MHz, MeOD) δP (ppm):
22.0. HRMS (ES-TOF+): m/z calcd for C43H54N4O6P
([M − CF3CO2]+) 753.3781, C43H55N4O6P ([M − CF3CO2 + H]2+)
377.1924. Found: 753.3786, 377.2102.
DO3A-xy-TXP trifluoroacetate. Following general procedure 3,
the title compound was prepared from 3c (0.33 g, 0.32 mmol)
and trifluoroacetic acid (3.3 mL) as a white solid (0.17 g, 57%).
1H NMR (400 MHz, MeOD) δH (ppm): 7.52 (3H, s, p-Ar), 7.49
(2H, d, 3JHH = 7.7 Hz, C6H ̲4), 7.18 (6H, d, 3JHP = 13.1 Hz, o-Ar),
7.00 (2H, d, 3JHH = 6.7 Hz, C6H ̲4), 4.68 (2H, d, 2JHP = 15.0 Hz,
CH̲2P), 4.24 (2H, s), 3.83 (2H, s), 3.64 (2H, s), 3.42–3.01 (18H,
m, macrocycle H̲), 2.36 (18H, s, CH̲3).
13C{1H}-NMR (100 MHz,
MeOD) δC (ppm): 161.6 (C̲vO), 161.3 (C ̲vO), 140.4 (d, 2JCP =
13.7 Hz, C̲6H4), 136.6 (d,
4JCP = 3.7 Hz, p-Ar), 132.0 (d,
4JCP =
5.5 Hz, C̲6H4), 131.5 (C̲6H4), 131.2 (d,
2JCP = 10.4 Hz, o-Ar),
118.3 (C ̲6H4), 117.5 (d, 1JCP = 84.7 Hz, i-Ar), 115.4 (m-Ar), 56.8,
54.4, 49.8 (broad s), 49.1 (broad s), 48.7 (broad s), 29.2 (d,
1JCP = 49.7 Hz, C̲H2P), 19.9 (C̲H3).
19F{1H}-NMR (377 MHz,
MeOD) δF (ppm): −72.6. 31P{1H}-NMR (162 MHz, MeOD)
δP (ppm): 22.3. HRMS (ES-TOF+): m/z calcd for C46H60N4O6P
([M − CF3CO2]+) 795.4250, C46H61N4OP ([M − CF3CO2 + H]2+)
398.2159. Found: 795.4326, 398.2164.
Radiochemistry procedures
General synthesis of [68Ga]Ga-DO3A-xy-TAP. The method-
ology was a modification of the procedure described by
Wang et al.28 To a solution of DO3A-xy-TAP trifluoroacetate
(approx. 100 μg) in NH4OAc buffer (0.1 M, 0.5 mL), an aliquot
of [68Ga]GaCl3 in 0.1 M HCl (approx. 150 MBq, 0.5 mL) was
added, and the resulting mixture was heated at 100 °C for
30 min to yield the desired product. Initial QC was performed
using iTLC and a mobile phase of 0.1 M disodium EDTA and
by the analytical HPLC method described previously.
Determination of LogD values. As an index for lipophilicity,
octanol/phosphate buffered saline (PBS) partition coefficient
(logD) values of the [68Ga]Ga-DO3A-xy-TAP compounds were
determined. A general methodology is as follows: aliquots of
the radiolabelled compound (10 µL, ∼4 kBq) were added to
vials containing a layered mixture of n-octanol (500 µL) and
PBS solution (pH 7.4, 500 µL). After vortex mixing for 1 min,
the mixture was centrifuged to separate the octanol–PBS
phases (104 rpm, 2 min), before aliquots of the two phases
(100 µL) were taken, and transferred into vials for counting.
Relative amounts of test compound in each phase were deter-
mined by an automatic gamma counter. The log D value was
reported as the average of data obtained in 6 independent
experiments.
In vitro tumour uptake study
For the tumour uptake study, MDA-MB 231 breast cancer cells
were used. [68Ga]Ga-DO3A-xy-TXP and [68Ga]Ga(III) were dis-
solved in serum-free cell medium to give a concentration of
1 MBq mL−1. 100 kBq aliquots of radiotracer were added to
cell samples (2 mL, 5 × 105 cells per mL) and incubated for
30 min. The cell supernatant was transferred to tubes for
gamma counting, before the cells were washed with PBS which
was subsequently added to the cell supernatant. The cells were
harvested by addition of trypsin (300 μL) and washing with a
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serum-free cell medium (700 μL). The supernatant and the
harvested cells were assayed in an automatic gamma counter
to determine percentage tracer uptake. The experiments were
performed in triplicate.
Langendorff isolated heart perfusion
Animals. Male Wistar rats (240–275 g; Charles River
Laboratories) were used for all experiments. Animal pro-
cedures were in accordance with the Animals (Scientific
Procedures) Act, UK, 1986.
The triple-γ-detector system. We developed a system for
characterizing the pharmacokinetics of radionuclide passage
through an isolated perfused heart comprising 3 orthogonally
orientated lead-collimated Na/I γ detectors positioned: (i) 3 cm
downstream of a radiotracer injection port on the arterial line,
15 cm upstream of the heart cannula (to provide a radiotracer
input function); (ii) directly opposite the heart itself; and (iii)
over the venous outflow line (to provide an output function).
Each was connected to a modified GinaSTAR instant thin-layer
chromatography system running Gina software (Raytest Ltd).
Experimental protocol. Rats were anaesthetized with sodium
pentobarbital and heparin sodium (200 mg kg−1 and
200 IU kg−1 respectively, i.p.) and their hearts were excised and
cannulated in the Langendorffmode as previously described.51
The hearts were perfused at 14 mL min−1 constant flow with
modified Krebs–Henseleit buffer (mKHB) containing NaCl
(118 mM), KCl (5.9 mM), MgSO4 (2.3 mM), NaHCO3 (25 mM),
EDTA (0.65 mM), glucose (11.1 mM) and CaCl2 (2.5 mM). The
mKHB was freshly prepared and filtered before use, and was
gassed with 95% O2 and 5% CO2 and used at 37 °C. A left ven-
tricular balloon was used to measure contractile function.
After a 10 min stabilization period, a bolus of radiotracer
(1 MBq) was injected into the arterial line, and the activity at
the arterial, heart and venous detectors was recorded (Fig. 4A).
After 15 minutes, a 6 μM solution of CCCP in mKHB heated to
37 °C was infused via the arterial line at 1.4 mL min−1, whilst
the flow rate at the peristaltic pump was reduced by 10%.
A further 1 MBq radiotracer bolus was administered 5 minutes
after the commencement of CCCP infusion. The radiotracer
retained after 15 min in both the healthy and CCCP-infused
hearts was reported as the average of the normalized activity
between 14–15 minutes after the radiotracer injection.
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